



Contacts:

Matt Niloff
Sr. Director of Products & Sales
Xcellerex, Inc.
508-683-2296

Xcellerex And Shire To Present Results Of First Known 1000 Liter Working Volume Perfusion Cell Culture Using Disposable Technology

Joint presentation to be featured at BioProcess International Conference & Exhibition in Boston

Marlborough, MA, September 5, 2007 – Xcellerex, Inc. and Shire Human Genetic Therapies, Inc. will jointly present the results of the first known successful use of disposable bioreactors in a large scale perfusion cell culture operation. The presentation will highlight the challenges and present data from a case study featuring a 1000 liter XDR Single-Use Bioreactor at the Xcellerex bioprocess facility in Marlborough, Massachusetts.

The case features perfusion culture of human cells through a seed train starting with 200 liter XDR bioreactors up to a 1000 liter XDR bioreactor. The perfusion operation was continued for one month, with 1000 liters harvested each day. Cells were separated in a disposable centrifuge.

Presenting for Shire will be Jin Yin, Senior Bioengineer, who will review the process and results. Xcellerex will be represented by Geoffrey Hodge, Vice President of Process Development and Technology, who will describe the equipment and process layout. The presentation is scheduled for Thursday, October 4, 2007 at 1:45 PM at the BioProcess International Conference & Exhibition at the Hynes Convention Center in Boston.

[Download Application Brief Here](#)

#

About Xcellerex, Inc.

Xcellerex is revolutionizing the way biomolecules are developed, manufactured and commercialized. The company's unique single-use component technology platform transforms biomanufacturing economics, enabling the development of biotherapeutics and vaccines, and dramatically improving the ability of Xcellerex and its partners to deploy manufacturing capacity. Xcellerex leverages its technology and services platform by: 1) commercializing its FlexFactories™ (complete, turnkey, modular production trains) and XDR™ (unique, single use component bioreactor systems); 2) building a portfolio of proprietary biotherapeutics and vaccines through creative alliances and in licensing; and 3) creatively structuring transactions around FlexFactories, XDRs and its pipeline. Learn more at www.xcellerex.com

For additional information, please contact:

For more information, contact:

Matt Niloff

Sr. Director of Products & Sales

Xcellerex, Inc.

email: mniloff@xcellerex.com

phone: 508-683-2296

Web: www.xcellerex.com

About XDR GMP Single-User Bioreactors

With a fully-integrated vessel and process control unit and in-house experts that operate them everyday, XDR single-use bioreactors from Xcellerex are the only GMP compliant stirred-tank systems that offer true plug-and-play, process-ready performance on arrival. XDRs deliver scalable performance from 40L to 2000L. 5:1 turndown means XDRs can operate at 20% of nominal volume, doing the work of multiple reactors. XDRs can be delivered and operational in 12 weeks.

More: www.xcellerex.com/xdr

###